WO2005066344A2 - New plasmids, their derivatives and fragments, their methods of manufacture and application - Google Patents

New plasmids, their derivatives and fragments, their methods of manufacture and application Download PDF

Info

Publication number
WO2005066344A2
WO2005066344A2 PCT/PL2005/000004 PL2005000004W WO2005066344A2 WO 2005066344 A2 WO2005066344 A2 WO 2005066344A2 PL 2005000004 W PL2005000004 W PL 2005000004W WO 2005066344 A2 WO2005066344 A2 WO 2005066344A2
Authority
WO
WIPO (PCT)
Prior art keywords
plasmid
sequence
plasmids
dna
fragment
Prior art date
Application number
PCT/PL2005/000004
Other languages
French (fr)
Other versions
WO2005066344A3 (en
Inventor
Andrzej Plucienniczak
Maria Ludwika Smorawinska
Renata Wolinowska
Diana Mikiewicz-Sygula
Agata Jagiello
Radoslaw Kaczanowski
Luiza Chojnacka
Grazyna Plucienniczak
Ewa Zielinska
Krystyna Strzezek
Alina Marciniak-Rusek
Original Assignee
Instytut Biotechnologii I Antybiotykow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biotechnologii I Antybiotykow filed Critical Instytut Biotechnologii I Antybiotykow
Priority to EP05704664A priority Critical patent/EP1704233A2/en
Publication of WO2005066344A2 publication Critical patent/WO2005066344A2/en
Publication of WO2005066344A3 publication Critical patent/WO2005066344A3/en
Priority to US11/482,550 priority patent/US7868148B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Definitions

  • the present invention relates to the method of obtaining a plasmid contained in a difficult to separate heterogeneous plasmid DNA fraction, particularly one containing plasmids of similar sizes.
  • Another aspect of the present invention are new plasmids obtained using the method according to the present invention, their derivatives and fragments, and the application of these products in biotechnology and medicine, particularly in gene therapy.
  • a DNA fragment gene we introduce into a cell, eg. Escherichia coli, will be expressed, but an unprotected foreign DNA fragment would shortly be degraded into nucleotides.
  • DNA fragments coding sequences of biologically significant proteins such as insulin, interferon or growth hormone are introduced into host cells via a vector.
  • Nectors are D ⁇ A molecules which are able to replicate autonomously in certain types of cells, and which ensure the amplification of the introduced D ⁇ A fragment, and in many cases the efficient expression of genes.
  • vectors are derivatives of naturally occurring plasmids.
  • a series of modifications need to be introduced into them. It is necessary to equip them with a marker, such as a gene or genes responsible for easily discerned phenotypic characteristics such as antibiotic resistance, and also to maximally reduce its molecular mass (the smaller the vector, the larger its "capacity” and ease of manipulation). It is also necessary to introduce a single restriction site of a given type which will be used for cloning, or to remove excess ones (two or more).
  • the nucleotide sequence should be known in its entirety, so that it may be discerned whether it contains known, or related, genes which may pose a threat to the health or even lives of people, plants or animals. Knowing the sequence also allows one to remove undesirable nucleotide sequences or add desirable ones such as immunogenic sequences in D ⁇ A vaccines . It has been determined that plasmid D ⁇ A causes the strongest immune response when CG sequences abut two purine bases (adenine or guanine) at the "C" side and two pyrimidines (thymine or cytosine) on the "G" side as described by Roman et al., ⁇ at.Med. 8:849-854, schematically represented by RRCGYY, and herewith indicated as imml. A particular case of this sequence which has a particularly strong immunogenic effect is imm2, which has two thymine bases at the "G" end.
  • CG units in bacterial plasmids are not methylated, whereas in vertebrates they usually are. It has been hypothesized that vertebrate organisms recognize a large frequency of unmethylated CG units as a danger signal, hence the amplified immune response. In gene therapy such an amplified immune response is undesirable, because it may lead to the destruction of the therapeutic protein and the plasmid vector. This is why it is preferable to use plasmids with low GC pair content in gene therapy.
  • the most useful vectors are the so-called expression vectors, which facilitate efficient synthesis of the proteins encoded by genes contained on the vector. Such vectors bear promoter sequences which facilitate transcription and translation, and sequences ensuring the stability of the synthesized protein.
  • transposons certain compound segments of DNA, called transposons, are able to place themselves in many portions of the host genome. This means that certain large DNA segments, known as insertion sequences (IS's), can, if they are located nearby, transpose themselves as a larger unit encompassing genes located between them. Complex units of this type form the transposon. They are found in Prokaryota, such as bacteria, but also in Eukaryota.
  • Tn5 is a 5.8 kilobase pair (kbp) segment of bacterial DNA, which can undergo insertion in many places in the chromosome, in plasmids, as well as in "latent” phages of gram-negative bacteria. It codes a bacterial resistance gene to aminoglycoside antibiotics, kanamycin and neomycin, as well as gentamycin resistance (G418) in eukaryotic cells.
  • G418 gentamycin resistance
  • transposone derived from transposone Tn5 useful in the production of mutants and rapid screening of long DNA sequences.
  • the transposone described encompasses a partial Tn5 transposone sequence with oligonucleotide SP6 and T7 phage primers, conveniently placed near opposite ends of the Tn5 transposone in question.
  • Classical methods used to isolate plasmid DNA, commonly used in laboratory practice are usually based on electrophoretic techniques. Despite their many pluses, which made them so popular, these techniques also do have certain limitations, particularly concerning their resolution.
  • the subject of the present invention is a method for obtaining a plasmid contained in a difficult to separate, heterogeneous fraction of plasmid DNA, particularly one containing various plasmids of similar sizes characterised in that the fraction of plasmid DNA contained in the total DNA of the source organism comes into contact with the enzyme transposase and the DNA of a transposone containing a selection marker gene; a microbiological host cell is transformed with a plasmid containing the transposone; the transfonnants obtained is grown under selection conditions matched to the selection marker used, and the plasmid containing the transposone is isolated from the amplified host cells.
  • the structure of the DNA containing the transposone is additionally analysed in order to establish the characteristics of the obtained plasmid.
  • the plasmid DNA fraction contains plasmids of similar sizes, present in significantly different quantities.
  • plasmid DNA containing the transposone is further modified. Preferentially, at least one of the following modifications is made: a restriction site is deleted or added, a selection marker gene is introduced, a gene coding a foreign protein is introduced, and/or a regulatory sequence is introduced. Equally preferentially, the multi-copy plasmid masking the presence of another plasmid is the plasmid pIGRK.
  • the plasmid present in lower quantities, masked by the presence of another plasmid is plasmid pIGMS31.
  • the next subject of the present invention is new plasmid isolated from the plasmid DNA fraction using the method according to invention, as defined above, its derivative or fragment.
  • plasmid pIGRK its derivative or fragment.
  • a plasmid according to invention contains at least one of the following modification: a restriction site is deleted or added, a selection marker gene is introduced, a gene coding a foreign protein is introduced, and/or a regulatory sequence is introduced, or any other arbitrary mutation.
  • a plasmid selected from the following group: pIGRKKAN, pIGRKKANde, pIGRKCM, pIGRKKANT7, pIGRKKhGH or one of their derivatives.
  • a fragment of the plasmid according to invention is an autonomous functional element, preferentially selected from the following group: transcription regulatory sequences, replication origins, and sequences coding reading frames.
  • it is a promoter.
  • it contains the nucleotide sequence, positions 1240 to 1367 of the plasmid pIGRKKAN sequence, its derivative or fragment.
  • the next subject of the present invention is plasmid pIGMS31 its derivative or fragment.
  • it contains at least one of the following modifications: a restriction site is deleted or added, a selection marker gene is introduced, a gene coding a foreign protein is introduced, and/or a regulatory sequence is introduced, or any other known, mutation.
  • plasmid selected from the following group: pIG S31KAN, pIGMS31KANT7, pIGMS31PR, pIGMS31PRH or one of their derivatives.
  • the next subject of the present invention is an application of the pIGRK or pIGMS31 plasmids or one of their derivatives or fragments according to invention, as defined above, in the expression of a sequence coding a polypeptide, or the regulation of such, a process.
  • the sequence coding the polypeptide codes a heterologous protein.
  • plasmid selected from the group containing pIGMS31PR, pIG]MS31PRH, pIGRKKhGH or one of their derivatives is used to produce human growth hormone or any heterologous protein.
  • the next subject of the present invention is an application of the nucleotide sequence containing the sequence from between positions 1240 to 1367 of the pIGRKKAN plasmid sequence, its derivative or fragment, to obtain promoter sequences.
  • the next subject of the present invention is applications of plasmids pIGRK or pIGMS31 or one of their derivatives or fragments according to invention, as defined above, to obtain plasmids meant for use in medicine, particularly gene therapy.
  • trie plasmids obtained possess lowered numbers of immunogenic sequences.
  • t ie plasmids obtained possess less than 20 immunogenic sequences, preferentially less than 10, and most preferentially no more than 5 such sequences.
  • the present invention thus provides an easy method of isolating a plasmid contained in a difficult to separate, heterogenous fraction of plasmid DNA, particularly one containing plasmids of similar sizes. This is testament to its superiority over other known methods of isolating plasmids, in particular electrophoretic methods.
  • the present invention provides new plasmids, obtained using the method according to the present invention, their derivatives and useful fragments.
  • the new plasmids and their derivatives may be used in the production of various constructs meant for biotechnology. In one embodiment, they may facilitate the stable and/or regulated, efficient expression of desired proteins.
  • Plasmids according to the present invention may also be used as regulatory elements in more complex expression systems.
  • a plasmid according to the present invention or its derivative may contain regulatory elements able to influence the expression of proteins coded by another plasmid (eg. a vector other than pIG), but located within the same cell.
  • Plasmids according to the present invention contain far fewer immunogenic sequences, which makes them better vectors or vector fragments for use in medicine, especially gene therapy.
  • pIGRKKAN and pIGMS31KAN contain 5 such undesirable immunogenic sequences each
  • pBR322 contains 38 of these sequences
  • pACYC184 contains 33
  • pUC18 contains 20 undesirable immunogenic sequences.
  • Plasmids obtained using a method according to the present invention may serve as sources of other, useful functional elements, useful in the production of other constructs.
  • a new transcription regulation element is described, with the characteristics of a strong transcriptional promoter.
  • Figure 1 and figure 2 represent the restriction map and nucleotide sequence respectively (sequence No. 1 in the sequence list) of the plasmid vector pIGRKKAN.
  • the immunogenic sequences imml and imml have been indicated on the map. Sequence from 1169 to 1199 encompass a multicloning site. Arrows indicate open reading frames for proteins coded by the plasmid. The frame located between nucleotides 87 and 959 codes for an aminoglycoside phosphotransferase, a protein involved in kanamycin resistance. The functions of the remaining open reading frames are unknown.
  • Figure 3 and figure 4 represent the restriction map and nucleotide sequence respectively (sequence No.
  • FIG. 5 represents a comparison of the sequence of the vector pIGRKKAN containing a nucleotide sequence recognized by the restriction endonuclease Nde with the same region in the vector pIGRKANde in which it has been removed. Two nucleotide bases, T and A, were removed from the plasmid vector which formed the so-called sticky ends of the sequence recognized by the restrictase Ndel.
  • Figure 6 and figure 7 represent the restriction map and nucleotide sequea ce respectively (sequence No. 3 in the sequence list) of the plasmid pIGRKCM. Tb e immunogenic sequences imml and imm2 have been indicated on the map. Arrows indicate open reading frames for proteins coded by the plasmid. The reading frame located between nucleotides 1639 and 2236 codes for chloramphenicol acetyltransferase (GAT) wananting chloramphenicol resistance. The functions of the remaining open reading frames are unknown.
  • Figure 8 and figure 9 represent the restriction map and nucleotide sequence respectively (sequence No. 4 in the sequence list) of the expression vector pIGRKANJT7.
  • Nucleotides between the Xbal and Pstl restriction sites form the favourpromoter-te ⁇ minator" region containing the transcription promoter and terminator for a gene coding the RNA polymerase in the bacteriophage T7 genome.
  • the frame located between, nucleotides 147 and 960 codes for an aminoglycoside phosphotransferase, a protein involved in kanamycin resistance. The functions of the remaining open reading frames are unknown.
  • Figure 10 and figure 11 represent the restriction map and nucleotide sequence respectively (sequence No. 5 in the sequence list) of the expression vector pIGRKKkGH.
  • Nucleotides between the BamHl (1169) and Ndel (2112) contain the promoter regions PI and P2 of the E. coli deo operon (Fischer and Short Gene. 17, 291-298(1982) .
  • the arrow from nucleotide 2113 (ATG) to 2916 (TAA) encompasses the sequence of a synthetic ubiquitin gene and human growth hormone.
  • the arrow from nucleotide 147 to nucleotide 960 encompasses a kanamycin resistance gene.
  • Figure 12 and figure 13 represent the restriction map and nucleotide sequence respectively (sequence No. 6 in the sequence list) of the plasmid pIGMS31PRF3. The promoter sequence is found between nucleotides 3699-3898.
  • the arrow from nucleotide 3918 (ATG) to 4721 (TAA) encompasses the sequence of a synthetic ubiquitin gene and human growth hormone.
  • Figure 14 represents the electrophoretic analysis of cell ly sates in a 15° o polyacrylamide gel.
  • molecular mass marker (97,0, 66,0, 45,0, 30,0 20,1 14,4 kDa).
  • Most strain E.coli DH5 ⁇ . 3.
  • the E.coli DH5 ⁇ strain transformed with plasmid pIGMS31PRH The arrow indicates the location of the fusion protein.
  • Example 1 Insertion of the EZ::TNTM ⁇ kan-2> transposone into plasmids from K. pneumoniae strain 287-w.
  • the modified transposone EZ::TNTM ⁇ kan-2> contains a grouping of sites recognized by enzymes often used in cloning, the so-called multicloning site.
  • the kit from Epicentre Technologies contains the transposase enzyme and primers for cloning the plasmid with the inserted transposon. The in vitro conditions have been selected by the producer so as to maximize the frequency of single insertions and to minimize multiple insertions transposone molecules into individual plasmid molecules. E.coli DH5 ⁇ cells with the kanamycin transposone were selected with LB medium containing (50 ⁇ g/ml).
  • Example 2 Nucleotide sequences of plasmids from K. pneumoniae strain 287-w. Sequencing of the plasmids surrounding the inserted kanamycin transposone showed that there were two plasmids of a similar size present (ca. 2500 base pairs) in Kpneumoniae strain 287-w. Thus the insertion of the kanamycin transposone allows one to identify different plasmids which are not identifiable electrophoretically due to an insignificant size difference and the masking effect of the multi-copy plasmid over the low copy number plasmid. Plasmids containing the kanamycin plasmid can be transformed into known strains of E. coli using kanamycin as a selection factor. In this way, E. coli strains are obtained containing single plasmids, which facilitates the amplification of their DNA for use in broadly understood cloning. Both plasmids have been fully sequenced.
  • the sequence of the plasmid pIGRKKAN contains 3578 base pairs with a GC content of 33,4%.
  • the plasmid sequence contains two imml and three imml sequences. 2 sequences recognized by the restriction enzyme Swal are found in the plasmid, which recognizes an 8-nucleotide sequence statistically occurring once per 40 000 base pairs in the E. coli genome.
  • Nucleotides 1-9 and 1241-1249 are so-called direct repeat sequences, of which one is additionally formed at the transposone insertion site.
  • Nucleotides from 10 to 1230 correspond to the 1221 base pairs of the inserted kanamycin transposone ⁇ Z::TNTM ⁇ KAN- 2>.
  • Nucleotides from 1240 to 3578 correspond to the sequence of the naturally occurring plasmid in K. pneumoniae strain 287-w.
  • the sequence of the naturally occurring plasmid pIGRK is 2338 base pairs long.
  • the sequence of plasmid pIGMS31KAN is 3750 base pairs long with a GC content of 36,8%.
  • the plasmid contains four imml and one imml sequences.
  • 3 Swal restriction enzyme recognition sequences are found in the plasmid, which recognizes an 8-nucleotide sequence statistically occurring once per 40 000 base pairs in the E. coli genome.
  • Nucleotides 1-9 and 2521-2529 are so-called direct repeat sequences of which one is additionally foraied through a 9 base pair repeat at the transposone insertion site.
  • Nucleotides 2530-3750 correspond to the 1221 base pairs of the inserted kanamycin transposone EZ::TNTM ⁇ KAN-2>. The sequence of the naturally occuring K.
  • pneumoniae strain 287-w plasmid is contained between nucleotides 1 and 2520. Nucleotides 2521 to 2529 are a simple repeat of the sequence 1-9, which is formed at the transposone insertion site.
  • the sequence of the naturally occurring plasmid pIGMS31 is 2520 base pairs long. Using BLASTN software, the sequence of the pIGMS31 plasmid was compared to the NCBI database. The homology of pIGMS31 to sequences found in the said database pertains to short DNA lengths, which allows one to state that this is a new, undescribed plasmid basing on a classification based on replicon sequence probability as described by Couturier et al, Microbiol. Rev.52, 375-395 (1988).
  • the translated amino acid sequence of the pIGMS31 plasmid was compared with a protein sequence database.
  • the cryptic plasmids from K. pneumoniae strain 287-w were used in a series of transformations and modifications in order to obtain new vectors.
  • Both plasmids pIGRKKAN and pIGMS31KAN may be used as vectors because they contain the so-called multicloning site, meaning a site with sequences recognized by restriction enzymes most commonly used in cloning.
  • the kanamycin resistance gene, isolated from transposone Tn903 also gives neomycin resistance in E. coli.
  • the examples below are of modifications of the plasmids pIGRKKAN and pIGMS31KAN.
  • Plasmid pIGRKAN contains one Ndel restriction site. It is a commonly used restriction site in cloning, because it contains an ATG sequence, the methionine codon which is the translation origin for most proteins.
  • the restriction site was removed using limited digestion with Mung Bean Nuclease. The effectiveness of the nuclease activity was assayed using Ndel digestion and through sequencing of the region which contained the recognition site for this enzyme.
  • the sequence of the portion of plasmid pIGRKKAN from which the Ndel restriction site was removed and designated as pIGRKKANde is presented in figure 5. Two T and A bases were removed, which formed the so-called sticky ends following Ndel digestion, thus giving the plasmid resistance to this enzyme.
  • the hypothetical reading frame was altered, which did not visibly influence the plasmid' s level of replication.
  • Example 4 Modification of the plasmid pIGRK through the insertion of a DNA fragment bearing chloramphenicol resistance.
  • a DNA fragment containing the chloramphenicol acetyltransferase (CAT) gene was inserted into plasmid pIGRK.
  • Plasmid pIGRK, digested with the restriction enzyme AsuII was ligated with a 952 base pair DNA fragment containing the CAT gene also digested with AsuII, from the pBW4 plasmid as described by Mikiewicz at al., Plasmid 38, 210- 219(1997).
  • Plasmid pIGRKCM, 3298 base pairs long, bearing the chloramphenicol resistance gene is represented in figures 6 and 7. Such a plasmid can be used in the production of an expression vector.
  • Example 5 Construction of an expression vector containing the T7 bacteriophage transcription promoter and tenninator.
  • Plasmid pIGMS31KAN and its derivative pIGMS31KANT7 are low-copy number plasmids, in contrast with plasmids pIGRKKAN and pIGRKKANT7, which occur in large numbers of copies in a bacterial cell.
  • Example 6 Using plasmid pIGMS31KAN to express the human growth hormone gene.
  • the promoter sequence of retron Ec86 described by Lim and Maas Cell 56: 891-904 and its following transcription terminator sequence were inserted into plasmid pIGMS31KAN.
  • the restriction sites for BamHI and Hindlll were used for this.
  • the plasmid formed was designated pIGMS31PR.
  • Plasmid pIGMS31PR was used to clone a gene coding a fusion protein composed of yeast ubiquitin and human growth hormone. The cloning made use of Ndel and Sail restriction sites.
  • the full sequence of the derivative plasmid, pIGMS31PRH is presented in figures 12 and 13.
  • the plasmid was used to transfonn cells of E. coli strain DH5 ⁇ .
  • Electrophoretic analysis of cell lysates showed the presence of a protein of a size corresponding to the fusion protein ubiquitin-growth hormone (figure 14).
  • Example 7 Using plasmid pIGRKKAN to express the gene coding human growth hormone.
  • DNA fragments containing the promoters PI and P2 from the deo operon of E. coli strain K-12 as described by Fischer and Short Gene 17:291-298, the growth hormone and modified ubiquitin gene fusion and the transcription terminator sequence were cloned into plasmid pIGRKKAN.
  • the restriction map of the recombined plasmid designated pIGRKKhGH is presented in figures 10 and 11.
  • the selection factor in the expression vector is the kanamycin resistance gene from the commercial transposone EZ::TNTM ⁇ KAN-2>.
  • the plasmid was used to transform cells of E. coli strain DH5 ⁇ . Electrophoretic analysis of lysates indicated the presence of a protein nearly identical in size with a UBI-hGH marker.
  • Example 8 Using the pIGRKKAN plasmid promoter in the expression of the gene coding human growth factor in the plasmid pIGMS31KAN.
  • the region of plasmid pIGRKKAN contained between nucleotides 1240 and 1367 was transferred to the polylinker sequence of plasmid pIGMS31KAN.
  • the gene coding the ubiquitin and human growth factor fusion protein and transcription terminator was placed downstream of this sequence. Electrophoretic analysis of cell lysates of E. coli DH5 ⁇ cells transformed with this plasmid indicated the presence of considerable quantities of a protein corresponding in size to the fusion protein. This means that the region of plasmid pIGRKKAN contained between nucleotides 1240 and 1367 contains a sequence which functions as a very efficient transcription promoter.
  • the region described contains the polypurine (AGGAGG) Shine-Dalgarno sequence between nucleotides 1356-1361 in close proximity to the ATG codon at the start of one of the reading frames in plasmid pIGRKAN.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

A method is described of obtaining a plasmid contained in a difficult to separate, heterogenous plasmid DNA fraction, particularly one containing various plasmids of similar sizes. Another aspect of the present invention are new plasmids obtained via the method according to the present invention, their derivatives and/or fragments, as well as the application of these products in biotechnology and medicine, particularly gene therapy.

Description

New plasmids, their derivatives and fragments, their methods of manufacture and application
The present invention relates to the method of obtaining a plasmid contained in a difficult to separate heterogeneous plasmid DNA fraction, particularly one containing plasmids of similar sizes. Another aspect of the present invention are new plasmids obtained using the method according to the present invention, their derivatives and fragments, and the application of these products in biotechnology and medicine, particularly in gene therapy. In modern biotechnology, we assume that a DNA fragment (gene) we introduce into a cell, eg. Escherichia coli, will be expressed, but an unprotected foreign DNA fragment would shortly be degraded into nucleotides. DNA fragments coding sequences of biologically significant proteins such as insulin, interferon or growth hormone are introduced into host cells via a vector. Nectors are DΝA molecules which are able to replicate autonomously in certain types of cells, and which ensure the amplification of the introduced DΝA fragment, and in many cases the efficient expression of genes.
Most often, vectors are derivatives of naturally occurring plasmids. However, to turn the latter into useful plasmid vectors, a series of modifications need to be introduced into them. It is necessary to equip them with a marker, such as a gene or genes responsible for easily discerned phenotypic characteristics such as antibiotic resistance, and also to maximally reduce its molecular mass (the smaller the vector, the larger its "capacity" and ease of manipulation). It is also necessary to introduce a single restriction site of a given type which will be used for cloning, or to remove excess ones (two or more). The nucleotide sequence should be known in its entirety, so that it may be discerned whether it contains known, or related, genes which may pose a threat to the health or even lives of people, plants or animals. Knowing the sequence also allows one to remove undesirable nucleotide sequences or add desirable ones such as immunogenic sequences in DΝA vaccines . It has been determined that plasmid DΝA causes the strongest immune response when CG sequences abut two purine bases (adenine or guanine) at the "C" side and two pyrimidines (thymine or cytosine) on the "G" side as described by Roman et al., Νat.Med. 8:849-854, schematically represented by RRCGYY, and herewith indicated as imml. A particular case of this sequence which has a particularly strong immunogenic effect is imm2, which has two thymine bases at the "G" end.
Furthermore, CG units in bacterial plasmids are not methylated, whereas in vertebrates they usually are. It has been hypothesized that vertebrate organisms recognize a large frequency of unmethylated CG units as a danger signal, hence the amplified immune response. In gene therapy such an amplified immune response is undesirable, because it may lead to the destruction of the therapeutic protein and the plasmid vector. This is why it is preferable to use plasmids with low GC pair content in gene therapy. In biotechnology, the most useful vectors are the so-called expression vectors, which facilitate efficient synthesis of the proteins encoded by genes contained on the vector. Such vectors bear promoter sequences which facilitate transcription and translation, and sequences ensuring the stability of the synthesized protein. There are expression vectors known under the control of strong promoters, whose synthesis can lead to accumulations of a given protein totalling 30% or even more of total cellular protein. Such vectors have been used for years in the production of many well known and useful proteins, particularly ones with desirable pharmacological properties.
It is known that certain compound segments of DNA, called transposons, are able to place themselves in many portions of the host genome. This means that certain large DNA segments, known as insertion sequences (IS's), can, if they are located nearby, transpose themselves as a larger unit encompassing genes located between them. Complex units of this type form the transposon. They are found in Prokaryota, such as bacteria, but also in Eukaryota.
Recently, many useful bacterial transposons have been discovered and characterised, among them one called Tn5. It is a 5.8 kilobase pair (kbp) segment of bacterial DNA, which can undergo insertion in many places in the chromosome, in plasmids, as well as in "latent" phages of gram-negative bacteria. It codes a bacterial resistance gene to aminoglycoside antibiotics, kanamycin and neomycin, as well as gentamycin resistance (G418) in eukaryotic cells. A restriction map of Tn5 was presented by Berg et al, Genetics 105, 813-828 (1983). Further information regarding the technology of Tn5 is contained in the review articles according to Berg and Berg, Bio/Technology 1, 417-435 (1983); and Berg and Berg, in Neidhardt et al., (ed.), "Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology" ASM, Washington, D.C., Chapter 63, p. 1,071-1,109 (1987).
Starting with naturally occurring transposons, a series of artificial constructs have been made, meant for use in genetic engineering. For example, patent description US5137829 presents a new DNA transposone derived from transposone Tn5 useful in the production of mutants and rapid screening of long DNA sequences. The transposone described encompasses a partial Tn5 transposone sequence with oligonucleotide SP6 and T7 phage primers, conveniently placed near opposite ends of the Tn5 transposone in question. Classical methods used to isolate plasmid DNA, commonly used in laboratory practice are usually based on electrophoretic techniques. Despite their many pluses, which made them so popular, these techniques also do have certain limitations, particularly concerning their resolution. They are not suitable for separating DNA fragments of similar sizes, especially when the mixture being separated contains decidedly varied amounts of the individual fragments. In this case, both fragments migrate through the electrophoretic gel as one band, and the presence of the less numerous fragment is masked by trie more numerous fragment. In the light of the above described in the state of the art, several technical problems may objectively be described, which are still awaiting resolution. It is worthwhile then to seek out natural plasmids with specific and useful properties from bacterial strains isolated from various sources. To realise this goal, it is desirable to obtain an easy method of isolating a plasmid contained in a heterogeneous, not easily separable fraction of plasmid DNA, particularly one containing various plasmids of similar sizes. It is particularly desirable to obtain new plasmids which could be used to produce new constructs useful in biotechnology, especially ones facilitating stable or regulated expression of desired proteins. In this context it is particularly desirable to obtain autonomic functional elements which could be used in the production of other, useful constructs. For example, it is still desirable to produce transcription regulatory elements, like strong transcriptional promoters. Furthermore, it is also desirable to obtain new plasmids, which would contain a decreased number of immunogenic sequences. Such plasmids could be a convenient source of various constructs designed for medical use, particularly gene therapy. The above described problems have been solved in the present invention. The subject of the present invention is a method for obtaining a plasmid contained in a difficult to separate, heterogeneous fraction of plasmid DNA, particularly one containing various plasmids of similar sizes characterised in that the fraction of plasmid DNA contained in the total DNA of the source organism comes into contact with the enzyme transposase and the DNA of a transposone containing a selection marker gene; a microbiological host cell is transformed with a plasmid containing the transposone; the transfonnants obtained is grown under selection conditions matched to the selection marker used, and the plasmid containing the transposone is isolated from the amplified host cells. Preferably, the structure of the DNA containing the transposone is additionally analysed in order to establish the characteristics of the obtained plasmid. Preferably, the plasmid DNA fraction contains plasmids of similar sizes, present in significantly different quantities. Preferably, plasmid DNA containing the transposone is further modified. Preferentially, at least one of the following modifications is made: a restriction site is deleted or added, a selection marker gene is introduced, a gene coding a foreign protein is introduced, and/or a regulatory sequence is introduced. Equally preferentially, the multi-copy plasmid masking the presence of another plasmid is the plasmid pIGRK. Preferably, the plasmid present in lower quantities, masked by the presence of another plasmid is plasmid pIGMS31. The next subject of the present invention is new plasmid isolated from the plasmid DNA fraction using the method according to invention, as defined above, its derivative or fragment.
The next subject of the present invention is plasmid pIGRK, its derivative or fragment. Preferably, a plasmid according to invention contains at least one of the following modification: a restriction site is deleted or added, a selection marker gene is introduced, a gene coding a foreign protein is introduced, and/or a regulatory sequence is introduced, or any other arbitrary mutation. Equally preferentially, it is a plasmid selected from the following group: pIGRKKAN, pIGRKKANde, pIGRKCM, pIGRKKANT7, pIGRKKhGH or one of their derivatives. Preferably, a fragment of the plasmid according to invention is an autonomous functional element, preferentially selected from the following group: transcription regulatory sequences, replication origins, and sequences coding reading frames. Preferentially, it is a promoter. Preferably, it contains the nucleotide sequence, positions 1240 to 1367 of the plasmid pIGRKKAN sequence, its derivative or fragment. The next subject of the present invention is plasmid pIGMS31 its derivative or fragment. Preferentially, it contains at least one of the following modifications: a restriction site is deleted or added, a selection marker gene is introduced, a gene coding a foreign protein is introduced, and/or a regulatory sequence is introduced, or any other known, mutation. Equally preferentially, it is a plasmid selected from the following group: pIG S31KAN, pIGMS31KANT7, pIGMS31PR, pIGMS31PRH or one of their derivatives. The next subject of the present invention is an application of the pIGRK or pIGMS31 plasmids or one of their derivatives or fragments according to invention, as defined above, in the expression of a sequence coding a polypeptide, or the regulation of such, a process. Preferentially, the sequence coding the polypeptide codes a heterologous protein. Preferentially, plasmid selected from the group containing pIGMS31PR, pIG]MS31PRH, pIGRKKhGH or one of their derivatives is used to produce human growth hormone or any heterologous protein. The next subject of the present invention is an application of the nucleotide sequence containing the sequence from between positions 1240 to 1367 of the pIGRKKAN plasmid sequence, its derivative or fragment, to obtain promoter sequences.
The next subject of the present invention is applications of plasmids pIGRK or pIGMS31 or one of their derivatives or fragments according to invention, as defined above, to obtain plasmids meant for use in medicine, particularly gene therapy. Preferentially, trie plasmids obtained possess lowered numbers of immunogenic sequences. Preferentially, t ie plasmids obtained possess less than 20 immunogenic sequences, preferentially less than 10, and most preferentially no more than 5 such sequences. To better illustrate the nature of the present invention, its description has been supplemented with a detailed discussion of example embodiments and examples located further in the description. It is not, however, the intention of the applicant to limit the scope of the present invention solely to the presented embodiments nor to the content of the examples below. Based on the revelation of the nature of the present invention stemming from this description in conjunction with commonly accessible knowledge, a specialist will be able to prepare other variants encompassed by the protection defined in the claims.
A series of bacterial strains were analysed, originating from strains collected from patients at The Children's Memorial Health Institute (CZD-Centrum Zdrowia Dziecka), during the search for new plasmids potentially useful in the construction of industrial or therapeutic expression vectors. Using agarose gel electrophoresis, the presence of a plasmid DNA fraction was observed in a clinical strain of Klebsiella pneumoniae, No. 287-w in the IBA system (No. 2324 in the CZD numeration). The electrophoresis image indicated the presence of one, multicopy plasmid (ca. 2500bp) as well as a few-copy one, four times larger than the former (ca. lOOOObp). Unexpectedly, application of the method according to the present invention facilitated the discernment of two plasmids of similar size (ca. 2500 base pairs) in a strain 287-w of K. pneumoniae, namely plasmids pIGRK and pIGMS31. The present invention thus provides an easy method of isolating a plasmid contained in a difficult to separate, heterogenous fraction of plasmid DNA, particularly one containing plasmids of similar sizes. This is testament to its superiority over other known methods of isolating plasmids, in particular electrophoretic methods.
Furthermore, the present invention provides new plasmids, obtained using the method according to the present invention, their derivatives and useful fragments. The new plasmids and their derivatives may be used in the production of various constructs meant for biotechnology. In one embodiment, they may facilitate the stable and/or regulated, efficient expression of desired proteins. Plasmids according to the present invention may also be used as regulatory elements in more complex expression systems. For example, a plasmid according to the present invention or its derivative may contain regulatory elements able to influence the expression of proteins coded by another plasmid (eg. a vector other than pIG), but located within the same cell. Plasmids according to the present invention, and their preferential derivatives, contain far fewer immunogenic sequences, which makes them better vectors or vector fragments for use in medicine, especially gene therapy. For example, when compared to other popular plasmids used as vectors, pIGRKKAN and pIGMS31KAN contain 5 such undesirable immunogenic sequences each, whereas the popular plasmid, pBR322 contains 38 of these sequences, pACYC184 contains 33, and pUC18 contains 20 undesirable immunogenic sequences.
Plasmids obtained using a method according to the present invention may serve as sources of other, useful functional elements, useful in the production of other constructs. For example, a new transcription regulation element is described, with the characteristics of a strong transcriptional promoter.
To better illustrate the content of the description, it has been supplemented with figures. Figure 1 and figure 2 represent the restriction map and nucleotide sequence respectively (sequence No. 1 in the sequence list) of the plasmid vector pIGRKKAN. The immunogenic sequences imml and imml have been indicated on the map. Sequence from 1169 to 1199 encompass a multicloning site. Arrows indicate open reading frames for proteins coded by the plasmid. The frame located between nucleotides 87 and 959 codes for an aminoglycoside phosphotransferase, a protein involved in kanamycin resistance. The functions of the remaining open reading frames are unknown. Figure 3 and figure 4 represent the restriction map and nucleotide sequence respectively (sequence No. 2 in the sequence list) of the plasmid vector pIGMS31KAN. The immunogenic sequences imml and imml have been indicated on the map. Sequence from 3651 to 3723 encompass a multicloning site. Anows indicate open reading frames for proteins coded by the plasmid. The reading frame located between nucleotides 2667 do 3479 codes for an aminoglycoside phosphotransferase, a protein involved in kanamycin resistance. The functions of the remaining open reading frames are unknown. Figure 5 represents a comparison of the sequence of the vector pIGRKKAN containing a nucleotide sequence recognized by the restriction endonuclease Nde with the same region in the vector pIGRKANde in which it has been removed. Two nucleotide bases, T and A, were removed from the plasmid vector which formed the so-called sticky ends of the sequence recognized by the restrictase Ndel.
Figure 6 and figure 7 represent the restriction map and nucleotide sequea ce respectively (sequence No. 3 in the sequence list) of the plasmid pIGRKCM. Tb e immunogenic sequences imml and imm2 have been indicated on the map. Arrows indicate open reading frames for proteins coded by the plasmid. The reading frame located between nucleotides 1639 and 2236 codes for chloramphenicol acetyltransferase (GAT) wananting chloramphenicol resistance. The functions of the remaining open reading frames are unknown. Figure 8 and figure 9 represent the restriction map and nucleotide sequence respectively (sequence No. 4 in the sequence list) of the expression vector pIGRKANJT7. Nucleotides between the Xbal and Pstl restriction sites form the „promoter-teπminator" region containing the transcription promoter and terminator for a gene coding the RNA polymerase in the bacteriophage T7 genome. The frame located between, nucleotides 147 and 960 codes for an aminoglycoside phosphotransferase, a protein involved in kanamycin resistance. The functions of the remaining open reading frames are unknown. Figure 10 and figure 11 represent the restriction map and nucleotide sequence respectively (sequence No. 5 in the sequence list) of the expression vector pIGRKKkGH. Nucleotides between the BamHl (1169) and Ndel (2112) contain the promoter regions PI and P2 of the E. coli deo operon (Fischer and Short Gene. 17, 291-298(1982) . The arrow from nucleotide 2113 (ATG) to 2916 (TAA) encompasses the sequence of a synthetic ubiquitin gene and human growth hormone. The arrow from nucleotide 147 to nucleotide 960 encompasses a kanamycin resistance gene. Figure 12 and figure 13 represent the restriction map and nucleotide sequence respectively (sequence No. 6 in the sequence list) of the plasmid pIGMS31PRF3. The promoter sequence is found between nucleotides 3699-3898. The arrow from nucleotide 3918 (ATG) to 4721 (TAA) encompasses the sequence of a synthetic ubiquitin gene and human growth hormone. Figure 14 represents the electrophoretic analysis of cell ly sates in a 15° o polyacrylamide gel. 1. molecular mass marker (97,0, 66,0, 45,0, 30,0 20,1 14,4 kDa). 2. Most strain E.coli DH5α. 3. The E.coli DH5α strain transformed with plasmid pIGMS31PR. 4. The E.coli DH5α strain transformed with plasmid pIGMS31PRH. The arrow indicates the location of the fusion protein.
Example 1. Insertion of the EZ::TN™<kan-2> transposone into plasmids from K. pneumoniae strain 287-w.
Strain 287-w is resistant to several antibiotics. It has proved impossible to ascertain whether the genes responsible for antibiotic resistance are found on one of the plasmids. Thus the plasmids isolated from the K. pneumoniae strain did not possess a selection marker, one of the basic features of every vector. The modified transposone Tn5, EZ::TN™<kan-2>, bearing a kanamycin resistance gene was inserted into plasmids isolated from the K. pneumoniae strain 287-w with the aid of the enzyme transposase. In addition to the kanamycin resistance gene, the modified transposone EZ::TN™<kan-2> (Epicentre Technologies, Madison WI, USA) contains a grouping of sites recognized by enzymes often used in cloning, the so-called multicloning site. In addition to the transposon, the kit from Epicentre Technologies contains the transposase enzyme and primers for cloning the plasmid with the inserted transposon. The in vitro conditions have been selected by the producer so as to maximize the frequency of single insertions and to minimize multiple insertions transposone molecules into individual plasmid molecules. E.coli DH5α cells with the kanamycin transposone were selected with LB medium containing (50μg/ml).
Example 2. Nucleotide sequences of plasmids from K. pneumoniae strain 287-w. Sequencing of the plasmids surrounding the inserted kanamycin transposone showed that there were two plasmids of a similar size present (ca. 2500 base pairs) in Kpneumoniae strain 287-w. Thus the insertion of the kanamycin transposone allows one to identify different plasmids which are not identifiable electrophoretically due to an insignificant size difference and the masking effect of the multi-copy plasmid over the low copy number plasmid. Plasmids containing the kanamycin plasmid can be transformed into known strains of E. coli using kanamycin as a selection factor. In this way, E. coli strains are obtained containing single plasmids, which facilitates the amplification of their DNA for use in broadly understood cloning. Both plasmids have been fully sequenced.
The restriction map and nucleotide sequence of the smaller plasmid, symbol pIGRKKAN, are presented in figures 1 and 2.
The restriction map and nucleotide sequence of the larger plasmid, symbol pIGMS31KAN are presented in figures 3 and 4.
The sequence of the plasmid pIGRKKAN contains 3578 base pairs with a GC content of 33,4%. The plasmid sequence contains two imml and three imml sequences. 2 sequences recognized by the restriction enzyme Swal are found in the plasmid, which recognizes an 8-nucleotide sequence statistically occurring once per 40 000 base pairs in the E. coli genome. Nucleotides 1-9 and 1241-1249 are so-called direct repeat sequences, of which one is additionally formed at the transposone insertion site. Nucleotides from 10 to 1230 correspond to the 1221 base pairs of the inserted kanamycin transposone ΕZ::TN™<KAN- 2>. Nucleotides from 1240 to 3578 correspond to the sequence of the naturally occurring plasmid in K. pneumoniae strain 287-w. The sequence of the naturally occurring plasmid pIGRK is 2338 base pairs long.
Using BLASTN software, the sequence of the pIGRK plasmid was compared to the NCBI database. The homology of pIGRK to sequences found in the said database pertains to short DNA lengths, which allows one to state that this is a new, undescribed plasmid basing on a classification based on replicon sequence probability as described by as described by Couturier et al., Microbiol. Rev.52, 375-395 (1988).
. Using the BLASTX program, the translated amino acid sequence of the pIGRK plasmid was compared with a protein sequence database. The post-translation amino acid sequences from the plasmid open reading frames of plasmid pIGRK have very little homology to proteins found in the SwissProt databases. These homologies are so low that it may be stated that the proteins coded for by pIGRK are unlike any other proteins.
The sequence of plasmid pIGMS31KAN is 3750 base pairs long with a GC content of 36,8%. The plasmid contains four imml and one imml sequences. 3 Swal restriction enzyme recognition sequences are found in the plasmid, which recognizes an 8-nucleotide sequence statistically occurring once per 40 000 base pairs in the E. coli genome. Nucleotides 1-9 and 2521-2529 are so-called direct repeat sequences of which one is additionally foraied through a 9 base pair repeat at the transposone insertion site. Nucleotides 2530-3750 correspond to the 1221 base pairs of the inserted kanamycin transposone EZ::TN™<KAN-2>. The sequence of the naturally occuring K. pneumoniae strain 287-w plasmid is contained between nucleotides 1 and 2520. Nucleotides 2521 to 2529 are a simple repeat of the sequence 1-9, which is formed at the transposone insertion site. The sequence of the naturally occurring plasmid pIGMS31 is 2520 base pairs long. Using BLASTN software, the sequence of the pIGMS31 plasmid was compared to the NCBI database. The homology of pIGMS31 to sequences found in the said database pertains to short DNA lengths, which allows one to state that this is a new, undescribed plasmid basing on a classification based on replicon sequence probability as described by Couturier et al, Microbiol. Rev.52, 375-395 (1988).
Using the BLASTX program, the translated amino acid sequence of the pIGMS31 plasmid was compared with a protein sequence database. The largest homology, 36%, of the amino acid sequence pertained solely to short lengths of the translated amino acid sequence. These insignificant homologies pertain to proteins taking part in the recombination process and replication initiation. These homologies are small enough that they also allow one to state that pIGMS31 is a new, undescribed plasmid.
The cryptic plasmids from K. pneumoniae strain 287-w were used in a series of transformations and modifications in order to obtain new vectors. Both plasmids pIGRKKAN and pIGMS31KAN may be used as vectors because they contain the so-called multicloning site, meaning a site with sequences recognized by restriction enzymes most commonly used in cloning. The kanamycin resistance gene, isolated from transposone Tn903 also gives neomycin resistance in E. coli. The examples below are of modifications of the plasmids pIGRKKAN and pIGMS31KAN. Example 3. Deletion of the Ndel restriction site.
Plasmid pIGRKAN contains one Ndel restriction site. It is a commonly used restriction site in cloning, because it contains an ATG sequence, the methionine codon which is the translation origin for most proteins. The restriction site was removed using limited digestion with Mung Bean Nuclease. The effectiveness of the nuclease activity was assayed using Ndel digestion and through sequencing of the region which contained the recognition site for this enzyme. The sequence of the portion of plasmid pIGRKKAN from which the Ndel restriction site was removed and designated as pIGRKKANde is presented in figure 5. Two T and A bases were removed, which formed the so-called sticky ends following Ndel digestion, thus giving the plasmid resistance to this enzyme. The hypothetical reading frame was altered, which did not visibly influence the plasmid' s level of replication.
Example 4. Modification of the plasmid pIGRK through the insertion of a DNA fragment bearing chloramphenicol resistance. A DNA fragment containing the chloramphenicol acetyltransferase (CAT) gene was inserted into plasmid pIGRK. Plasmid pIGRK, digested with the restriction enzyme AsuII, was ligated with a 952 base pair DNA fragment containing the CAT gene also digested with AsuII, from the pBW4 plasmid as described by Mikiewicz at al., Plasmid 38, 210- 219(1997). Plasmid pIGRKCM, 3298 base pairs long, bearing the chloramphenicol resistance gene is represented in figures 6 and 7. Such a plasmid can be used in the production of an expression vector.
Example 5. Construction of an expression vector containing the T7 bacteriophage transcription promoter and tenninator.
Two expression vectors were constructed containing a transcription promoter and terminator for the gene coding the RNA polymerase in the T7 bacteriophage genome, based on the plasmids pIGMS31KAN and pIGRKKAN. The restriction maps are represented in figures 8 and 9, respectively. Plasmid pIGMS31KAN and its derivative pIGMS31KANT7 are low-copy number plasmids, in contrast with plasmids pIGRKKAN and pIGRKKANT7, which occur in large numbers of copies in a bacterial cell. Example 6. Using plasmid pIGMS31KAN to express the human growth hormone gene. The promoter sequence of retron Ec86 described by Lim and Maas Cell 56: 891-904 and its following transcription terminator sequence were inserted into plasmid pIGMS31KAN. The restriction sites for BamHI and Hindlll were used for this. The plasmid formed was designated pIGMS31PR. Plasmid pIGMS31PR was used to clone a gene coding a fusion protein composed of yeast ubiquitin and human growth hormone. The cloning made use of Ndel and Sail restriction sites. The full sequence of the derivative plasmid, pIGMS31PRH is presented in figures 12 and 13. The plasmid was used to transfonn cells of E. coli strain DH5α. Electrophoretic analysis of cell lysates showed the presence of a protein of a size corresponding to the fusion protein ubiquitin-growth hormone (figure 14). Example 7. Using plasmid pIGRKKAN to express the gene coding human growth hormone.
DNA fragments containing the promoters PI and P2 from the deo operon of E. coli strain K-12 as described by Fischer and Short Gene 17:291-298, the growth hormone and modified ubiquitin gene fusion and the transcription terminator sequence were cloned into plasmid pIGRKKAN. The restriction map of the recombined plasmid designated pIGRKKhGH is presented in figures 10 and 11. The selection factor in the expression vector is the kanamycin resistance gene from the commercial transposone EZ::TN™<KAN-2>. The plasmid was used to transform cells of E. coli strain DH5α. Electrophoretic analysis of lysates indicated the presence of a protein nearly identical in size with a UBI-hGH marker. Example 8. Using the pIGRKKAN plasmid promoter in the expression of the gene coding human growth factor in the plasmid pIGMS31KAN.
The region of plasmid pIGRKKAN contained between nucleotides 1240 and 1367 was transferred to the polylinker sequence of plasmid pIGMS31KAN. The gene coding the ubiquitin and human growth factor fusion protein and transcription terminator was placed downstream of this sequence. Electrophoretic analysis of cell lysates of E. coli DH5α cells transformed with this plasmid indicated the presence of considerable quantities of a protein corresponding in size to the fusion protein. This means that the region of plasmid pIGRKKAN contained between nucleotides 1240 and 1367 contains a sequence which functions as a very efficient transcription promoter. The region described contains the polypurine (AGGAGG) Shine-Dalgarno sequence between nucleotides 1356-1361 in close proximity to the ATG codon at the start of one of the reading frames in plasmid pIGRKAN. Literature l.Berg,D.E., and Berg,C.M.(1983). The prokaryotic transposable element Tn5. Biotechnology 1, 417-435. 2.Berg,D.E., Schmandt, M.A., and Lowe J.B.(1983) Specificity of transposon Tn5 Insertion.Genetics 105(4), 813-828
3. Berg and Berg, in Neidhardt et al., (ed.), "Escherichia coli and Salmonella iyphimurium: Cellular and Molecular Biology" ASM, Washington, D.C., Chapter 63, p. 1,071-1,109 (1987).
3. Couturier, M., Bex, F., Bergquist, P. L., and Maas, W. K., (1988) Identification and classification of bacterial plasmids. Microbiol. Rev., 52, 375-395.
4. Fischer M., and Short S.A. 1982. The cloning of the Escherichia coli deoxyribonucleoside operon. Gene. 17 291-298). 5. Lim D., Maas W.K. (1989) Reverse transcriptase-dependent synthesis of a covalently linked, branched DNA-RNA compound in E.coli B. Cell 56, 891-904. 6. Mikiewicz, D., Wrόbel, B., Wςgrzyn, G., and Plucienniczak, A. (1997) Isolation and and characterization of a ColEl-like plasmid from Enterobacter agglomerans with a novel variant oϊrom gene. Plasmid, 38, 210-219. 7. Roman, M., Martin-Orozoco, E., Goodman,J.S., Nguyen, M.D., Sato, Y., Ronaghy, A., Kornbluth, R.S., Ricliman, D. D., Carson, D. A., and Raz, E. (1997). Immunostimulatory DNA sequences function as T helper- 1 -promoting adjuvants. Nat. Med. 8, 849-854.

Claims

15Claims
1. A Method for obtaining a plasmid contained in a difficult to separate, heterogenous fraction of plasmid DNA, particularly one containing various plasmids of similar sizes characterised in that the fraction of plasmid DNA contained in the total DNA of the source organism comes into contact with the enzyme transposase and the DNA of a transposone containing a selection marker gene; a microbiological host cell is transfected with a plasmid containing the transposon; the transformant obtained is grown under selection conditions matched to the selection marker used, and the plasmid containing the transposone is isolated from the amplified host cells.
2. A method according to Claim 1, characterised in that the structure of the DNA containing the transposone is additionally analysed in order to establish the characteristics of the obtained plasmid.
3. A method according to Claim 1, characterised in that the plasmid DNA fraction contains plasmids of similar sizes, present in significantly different quantities.
4. A method according to Claim 1, characterised in that DNA isolated from the plasmid containing the transposone is further modified.
5. A method according to Claim 4, characterised in that at least one of the following modifications is made: a restriction site is deleted or added, a selection marker gene is introduced, a gene coding a foreign protein is introduced, and/or a regulatory sequence is introduced.
6. A method according to Claim 3, characterised in that the multi-copy plasmid masking the presence of another plasmid is the plasmid pIGRK.
7. A method according to Claim 3 or 6, characterised in that the plasmid present in lower quantities, masked by the presence of another plasmid is plasmid pIGRMS31.
8. A new plasmid isolated from the plasmid DNA fraction using the method according to Claims 1 to 7, its derivative or fragment.
9. The plasmid pIGRK, its derivative or fragment.
10. A plasmid according to Claim 9, characterised in that it contains at least one of the following modification: a restriction site is deleted or added, a selection marker gene is introduced, a gene coding a foreign protein is introduced, and/or a regulatory sequence is introduced, or any other arbitrary mutation.
11. A plasmid according to Claim 9 or 10, characterised in that it is a plasmid selected from the following group: pIGRKKAN, pIGRKKANde, pIGRKCM, pIGRKKANT7, pIGRKKhGH or one of their derivatives.
12. A fragment according to Claim 9, characterised in that it is an autonomous functional element, preferentially selected from the following group: transcription regulatory sequences, replication origins, and sequences coding reading frames.
13. A fragment according to Claim 9 or 12, characterised in that it is a promoter.
14. A fragment according to Claim 13, characterised in that it contains the nucleotide sequence, positions 1240 to 1367 of the plasmid pIGRKKAN sequence, its derivative or fragment.
15. Plasmid pIGMS31 its derivative or fragment.
16. A plasmid according to Claim 15, characterised in that it contains at least one of the following modifications: a restriction site is deleted or added, a selection marker gene is introduced, a gene coding a foreign protein is introduced, and/or a regulatory sequence is introduced, or any other known mutation.
17. A plasmid according to Claim 15 or 16, characterised in that it is a plasmid selected from the following group: pIGMS31KAN, pIGMS31KANT7, pIGMS31PR, pIGMS31PRH or one of their derivatives.
18. An application of the pIGRK or pIGMS31 plasmids or one of their derivatives or fragments according to one of Claims 8 to 17 in the expression of a sequence coding a polypeptide, or the regulation of such a process.
19. An application according to Claim 18, characterised in that the sequence coding the polypeptide codes a heterologous protein.
20. An application according to Claim 18 or 19, characterised in that the plasmid selected from the group containing pIGMS31PR, pIGMS31PRH, pIGRKKhGH or one of their derivatives is used to produce human growth hormone or any heterologous protein.
21. An application of the nucleotide sequence containing the sequence from between positions 1240 to 1367 of the pIGRKKAN plasmid sequence, its derivative or fragment, to obtain promoter sequences.
22. Applications of plasmids pIGRK or pIGMS31 or one of their derivatives or fragments according to one of Claims 8 to 17 to obtain plasmids meant for use in medicine, particularly gene therapy.
23. An application according to Claim 22, characterised in that the plasmids obtained possess lowered numbers of immunogenic sequences.
24. An application according to Claim 23, characterised in that the plasmids obtained possess less than 20 immunogenic sequences, preferentially less than 10, and most preferentially no more than 5 such sequences.
PCT/PL2005/000004 2004-01-09 2005-01-10 New plasmids, their derivatives and fragments, their methods of manufacture and application WO2005066344A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05704664A EP1704233A2 (en) 2004-01-09 2005-01-10 New plasmids, their derivatives and fragments, their methods of manufacture and application
US11/482,550 US7868148B2 (en) 2004-01-09 2006-07-07 Plasmids, their derivatives and fragments, their methods of manufacture and application

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLP.364295 2004-01-09
PL364295A PL213561B1 (en) 2004-01-09 2004-01-09 New plasmides, their derivatives and fragments, the method for their obtaining and application

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/482,550 Continuation-In-Part US7868148B2 (en) 2004-01-09 2006-07-07 Plasmids, their derivatives and fragments, their methods of manufacture and application

Publications (2)

Publication Number Publication Date
WO2005066344A2 true WO2005066344A2 (en) 2005-07-21
WO2005066344A3 WO2005066344A3 (en) 2006-04-20

Family

ID=34748263

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/PL2005/000003 WO2005066208A2 (en) 2004-01-09 2005-01-10 Method for production of recombinant growth hormone in form of hybrid protein
PCT/PL2005/000004 WO2005066344A2 (en) 2004-01-09 2005-01-10 New plasmids, their derivatives and fragments, their methods of manufacture and application

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/PL2005/000003 WO2005066208A2 (en) 2004-01-09 2005-01-10 Method for production of recombinant growth hormone in form of hybrid protein

Country Status (4)

Country Link
US (2) US7892787B2 (en)
EP (2) EP1706494B1 (en)
PL (2) PL213561B1 (en)
WO (2) WO2005066208A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009157926A1 (en) * 2008-06-25 2009-12-30 Braasch Biotech Llc Chloramphenicol acetyl transferase (cat)-defective somatostatin fusion protein and uses thereof
EP2371853A2 (en) 2008-07-04 2011-10-05 Instytut Biotechnologii I Antybiotykow Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
US8425914B2 (en) 2008-06-25 2013-04-23 Braasch Biotech Llc Methods for enhanced somatostatin immunogenicity in the treatment of obesity
WO2013176560A1 (en) 2012-05-23 2013-11-28 Instytut Biotechnologii i Antybiotyków An insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes
US10441652B2 (en) 2014-08-21 2019-10-15 Braasch Biotech Llc Methods for improving immunological response in vaccinated animals

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1841862T3 (en) 2005-01-10 2013-10-31 Inst Biotechnologii I Antybiotykow A ubp1 protease mutant,and its coding sequence, their applications and heterogonous protein expression system
US20140045211A1 (en) * 2011-03-24 2014-02-13 The Regents Of The University Of California High level production of recombinant proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693475A1 (en) * 1992-07-08 1994-01-14 Rhone Poulenc Rorer Sa Identification and opt. cloning of gene promoters - using DNA library contg. transposon bearing selectable marker

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212058A (en) * 1990-05-09 1993-05-18 Massachusetts Institute Of Technology Nucleic acid encoding ubiquitin-specific proteases
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
IT1247484B (en) * 1991-03-22 1994-12-17 Ceinge Societa Consortile A R INTERLEUCHINA PREPARATION METHOD 6
US5437986A (en) * 1994-06-22 1995-08-01 Schering Corporation Extraction of heterologous insoluble proteins from bacteria
AU739394B2 (en) * 1998-08-27 2001-10-11 Lg Chemical Limited Process for the preparation of active somatotropin from inclusion bodies
AUPP582198A0 (en) * 1998-09-10 1998-10-01 Bresagen Limited Modified human growth hormone
RU2141531C1 (en) * 1999-05-26 1999-11-20 Российское акционерное общество открытого типа "Биопрепарат" Method of recombinant human insulin preparing
WO2003010204A1 (en) * 2001-07-26 2003-02-06 Advanced Protein Technologies Corp. Process for preparation of polypeptides of interest from fusion peolypeptides
PL201867B1 (en) * 2003-05-02 2009-05-29 Inst Biotechnologii I Antybiot UBP1 protease mutant and its coding sequence, their application as well as products and methods for their obtaining

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693475A1 (en) * 1992-07-08 1994-01-14 Rhone Poulenc Rorer Sa Identification and opt. cloning of gene promoters - using DNA library contg. transposon bearing selectable marker

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DERAGON J M ET AL: "Plasmid from photosynthetic bacterium Ectothiorhodospira Sp. carries a transposable streptomycin resistance gene." PLASMID. MAY 1990, vol. 23, no. 3, May 1990 (1990-05), pages 226-236, XP009052617 ISSN: 0147-619X *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8425914B2 (en) 2008-06-25 2013-04-23 Braasch Biotech Llc Methods for enhanced somatostatin immunogenicity in the treatment of obesity
US7722881B2 (en) 2008-06-25 2010-05-25 Braasch Biotech Llc Chloramphenicol acetyl transferase (CAT)-defective somatostatin fusion protein and uses thereof
US7943143B2 (en) 2008-06-25 2011-05-17 Braasch Biotech Llc Chloramphenicol acetyl transferase (CAT)-defective somatostatin fusion protein and uses thereof
CN102105163A (en) * 2008-06-25 2011-06-22 布拉施生物技术有限责任公司 Chloramphenicol acetyl transferase (CAT)-defective somatostatin fusion protein and uses thereof
US8367073B2 (en) 2008-06-25 2013-02-05 Braasch Biotech, LLC Chloramphenicol acetyl transferase (CAT)-defective somatostatin fusion protein and uses thereof
WO2009157926A1 (en) * 2008-06-25 2009-12-30 Braasch Biotech Llc Chloramphenicol acetyl transferase (cat)-defective somatostatin fusion protein and uses thereof
CN102105163B (en) * 2008-06-25 2014-12-10 布拉施生物技术有限责任公司 Chloramphenicol acetyl transferase (CAT)-defective somatostatin fusion protein and uses thereof
KR101555731B1 (en) 2008-06-25 2015-09-25 브라아쉬 바이오테크 엘엘씨 - chloramphenicol acetyl transferase-defective somatostatin fusion protein and uses thereof
EP2371853A2 (en) 2008-07-04 2011-10-05 Instytut Biotechnologii I Antybiotykow Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
US8618048B2 (en) 2008-07-04 2013-12-31 Instytut Biotechnologii i Antybiotyków Insulin analogues of prolonged activity
WO2013176560A1 (en) 2012-05-23 2013-11-28 Instytut Biotechnologii i Antybiotyków An insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes
US10441652B2 (en) 2014-08-21 2019-10-15 Braasch Biotech Llc Methods for improving immunological response in vaccinated animals
US11400151B2 (en) 2014-08-21 2022-08-02 Braasch Biotech Llc Methods for improving immunological response in vaccinated animals

Also Published As

Publication number Publication date
WO2005066208A2 (en) 2005-07-21
EP1706494A2 (en) 2006-10-04
US7868148B2 (en) 2011-01-11
EP1706494B1 (en) 2012-07-04
WO2005066344A3 (en) 2006-04-20
PL1706494T3 (en) 2013-03-29
PL213561B1 (en) 2013-03-29
PL364295A1 (en) 2005-07-11
EP1704233A2 (en) 2006-09-27
US20080160570A1 (en) 2008-07-03
US7892787B2 (en) 2011-02-22
US20070134217A1 (en) 2007-06-14
WO2005066208A3 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
US6291245B1 (en) Host-vector system
Love et al. Stable high-copy-number bacteriophage λ promoter vectors for overproduction of proteins in Escherichia coli
US7868148B2 (en) Plasmids, their derivatives and fragments, their methods of manufacture and application
DK166784B1 (en) RECOMBINANT DNA SEQUENCE, A MICROORGANISM CONTAINING THE SEQUENCE AND A PROCEDURE FOR PREPARING AN EUCARYOT PROTEIN
EP0163406B1 (en) Novel polypeptide expression method
EP0211047B1 (en) Arab promoters and method of producing polypeptides, includinn cecropins, by microbiological techniques
Ishino et al. Nucleotide sequence of the lig gene and primary structure of DNA ligase of Escherichia coli
CN111278979A (en) Production method of recombinant escherichia coli asparaginase
US20080233614A1 (en) Production of recombinant collagenases colg and colh in escherichia coli
WO1999016858A1 (en) Expression control sequences
CN115427071A (en) Compositions comprising LTB and pathogenic antigens and uses thereof
EP2356142B1 (en) E. coli bl21 strain lacking a functional group ii capsular gene cluster.
JPS63289A (en) Increase in protein production using novel liposome bonding area in bacteria
CN109628431B (en) Human lysozyme coding gene and method for expressing same in pichia pastoris and application
MXPA04005717A (en) Expression system.
US20100041101A1 (en) Expression system for recombinant human arginase i
EP0063494B1 (en) Method for producing protein from a microorganism, microorganisms for use in such method and creation thereof, vectors for use in said creation, and protein produced thereby, and transformant culture derived from said microorganisms
EP0170266B1 (en) Process for producing protein, and vector, recombinant dna and transformant used therefor
US20030153049A1 (en) Escherichia coli strain secreting human granulocyte colony stimulating factor (g-csf)
JPS61224991A (en) Exclusive lyposome and its use
EP3904520A1 (en) Gene expression cassette for expressing n-terminal methionine-truncated protein of interest and method for producing n-terminal methionine-truncated protein of interest by using same
IE58915B1 (en) New expression control sequence
US20040175705A1 (en) Systems for expression of heterologous proteins in m capsulatus
EP1582587B1 (en) Cold-induced expression vector
US20070031937A1 (en) Co-expression of recombinant proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11482550

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005704664

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005704664

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11482550

Country of ref document: US